Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:ruxolitinib
|
| gptkbp:age |
adults
children 12 years and older |
| gptkbp:approvalYear |
2021
|
| gptkbp:ATCCode |
D11AH06
|
| gptkbp:contraindication |
hypersensitivity to ruxolitinib
|
| gptkbp:form |
topical cream
|
| gptkbp:genericName |
gptkb:ruxolitinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Opzelura
|
| gptkbp:indication |
gptkb:atopic_dermatitis
vitiligo |
| gptkbp:manufacturer |
gptkb:Incyte_Corporation
|
| gptkbp:mechanismOfAction |
Janus kinase inhibitor
|
| gptkbp:pregnancyCategory |
not established
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
topical
|
| gptkbp:sideEffect |
headache
acne nasopharyngitis application site reaction |
| gptkbp:bfsParent |
gptkb:Incyte
|
| gptkbp:bfsLayer |
6
|